Ozempic or Wegovy: which is more effective for weight loss?

Step 1, understanding that Ozempic and Wegovy are the same drug used differently

A common assumption is that Ozempic must be stronger because it's the one people talk about most online. The reality is almost the opposite. Ozempic was simply approved first, for type 2 diabetes, at doses of 0.5 mg or 1 mg (and later 2 mg in some countries). Wegovy came after, reformulated and repackaged specifically for weight management, at a 2.4 mg weekly maintenance dose.

Both are semaglutide, a GLP-1 receptor agonist that slows gastric emptying and signals the brain to reduce appetite. The mechanism is identical. What changes is the therapeutic goal and the dose ceiling the regulator has approved for each use. Using Ozempic to try to achieve Wegovy's weight-loss results is not what the medicine is licensed for in the UK, and it isn't something a responsible prescriber should offer outside a diabetes diagnosis. The NHS medicines page for semaglutide sets this out clearly.

For anyone searching specifically for how the two products compare in clinical practice, a more detailed side-by-side breakdown is available on our Wegovy vs Ozempic page. If you want to go further and understand what the key differences between Ozempic and Wegovy actually are, that page covers everything from licensing to dosing in one place.

Step 2, reading the trial evidence for each licensed dose

The STEP 1 trial randomised over 1,900 adults with obesity to either semaglutide 2.4 mg or placebo, both alongside lifestyle changes, over 68 weeks. Participants taking semaglutide lost an average of approximately 15% of body weight, compared with under 3% in the placebo group. That result underpinned Wegovy's UK licence for weight management.

Ozempic's diabetes trials were designed around blood-sugar control, not weight. Participants did lose weight, but the primary endpoint wasn't fat reduction and the doses were lower. Comparing Ozempic's incidental weight-loss data directly against Wegovy's purpose-built weight-management trials isn't a fair test, it's a bit like judging a car by lap times when it was built for fuel economy.

The MHRA approved a higher Wegovy dose of 7.2 mg in January 2026, with a dedicated single-dose pen following in April 2026. Trials at that level showed around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide (Mounjaro). If you're curious about how much more weight Wegovy produces compared with Ozempic's diabetes doses, that page walks through the figures in detail.

Step 3, what is actually licensed for weight loss in the UK, and how to access it

In the UK, the two medicines licensed for weight management are Wegovy (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly). Ozempic is not licensed for weight loss here; if you've been told you can get it for that purpose without a diabetes diagnosis, that's worth treating with real caution.

Wegovy is available through specialist NHS weight management services under NICE guidance, though waiting lists are often long. Private prescribing is the alternative route for people who don't meet current NHS thresholds or prefer not to wait. Our weight-loss treatment overview explains both routes and what the clinical assessment involves.

For those wanting to understand the injection side of things, our guide to the most effective injection site for Wegovy covers technique and rotation. And if you're weighing up whether Wegovy is a better fit for you personally than Ozempic or other options, the page on whether Wegovy outperforms Ozempic goes into the clinical nuance.

Cost is naturally part of this decision too. Private Wegovy pricing varies by dose and provider; our Wegovy treatment page outlines what's included in a consultation-led private prescription, so you're comparing like with like rather than headline figures.

At nume (at our pharmacy) every consultation is read by a GPhC-registered Independent Prescriber, not software. A real clinician reviews your answers the same day and decides whether treatment is appropriate. If you'd like a prescriber to talk through which licensed weight-management option suits your circumstances, you can speak to our prescribers through a free consultation, no obligation.